Bioretec Ltd Announces Financial Reporting Schedule
Bioretec Ltd has shared its plans regarding important financial disclosures for the upcoming year. This announcement outlines when stakeholders can expect key reports from the medical device innovator.
Upcoming Financial Reports
In 2025, Bioretec will release critical financial documents designed to keep investors informed. Here is the schedule of the reports:
Financial Statements Bulletin
The first key report will be the financial statements bulletin, covering data from January to December 2025. This bulletin is expected to be published on February 13, 2025.
Annual Report and Financial Statements
Following this, Bioretec will provide its annual report, along with the Board of Directors' report and detailed financial statements for the year 2025, set to be released on March 13, 2026.
Quarterly Business Reviews
Investors can also look forward to quarterly business reviews. The first of these, focusing on the business activities from January to March 2026, will be published on May 14, 2026.
Half-Year and Business Reviews
The half-year report covering January to June 2026 will be available on August 13, 2026, followed by another business review that reports on the activities of January to September 2026, expected on November 12, 2026.
Details on the Annual General Meeting
In conjunction with the financial reporting plans, Bioretec Ltd's Annual General Meeting (AGM) has been slated for May 8, 2026. Further arrangements regarding the AGM will be communicated by the company's Board of Directors as the date approaches.
Company Leadership Contact
For further inquiries, stakeholders are encouraged to reach out to Sarah van Hellenberg Hubar-Fisher, the CEO, contactable at +31 6 1544 8736.
Certified Adviser Information
Bioretec Ltd maintains a close relationship with Nordic Certified Adviser AB, who can be reached at +46 70 551 67 29 for advisory support.
About Bioretec Ltd
Bioretec Ltd is a Finnish pioneer in medical devices, focused on enhancing orthopedic care through fully biodegradable implant technologies. The company is renowned for its ability to produce innovative solutions that improve patient outcomes and accelerate recovery processes in orthopedic surgery.
The company offers a distinct range of products designed to promote healing by integrating with the body's biological structures. One of the latest advancements is the RemeOs™ product line, utilizing a high-performance magnesium alloy and hybrid composite, available in approximately 40 countries. These implants dissolve naturally, enhancing the healing of fractures without requiring removal surgery.
Additionally, Bioretec's Activa product line consists of bioabsorbable orthopedic implants made from a proprietary PLGA material. These products are both CE marked and FDA approved, suitable for various patients, including pediatric cases.
With a commitment to advancing orthopedic treatment, Bioretec is dedicated to creating innovative, patient-friendly solutions that lead to improved healthcare experiences.
Frequently Asked Questions
What financial reports will Bioretec publish in 2025?
Bioretec plans to provide a financial statements bulletin, an annual report with detailed financial statements, and several quarterly business reviews.
When is Bioretec's Annual General Meeting scheduled?
The Annual General Meeting will take place on May 8, 2026. Details will be provided by the Board of Directors.
Who can I contact for more information about Bioretec?
For inquiries, please contact CEO Sarah van Hellenberg Hubar-Fisher at +31 6 1544 8736.
What is the focus of Bioretec's innovation?
Bioretec is focused on developing biodegradable implant technologies to enhance orthopedic care and accelerate healing processes.
How is Bioretec shaping the future of orthopedic treatment?
By designing fully absorbable implants, Bioretec aims to create effective and patient-friendly solutions, ultimately improving surgical outcomes and recovery experiences.
